

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>JENSEN MICHAEL VANGSTED</u>  (Last) (First) (Middle) C/O SYNLOGIC, INC. 301 BINNEY STREET, SUITE 402  (Street) CAMBRIDGE MA 02142  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>SYNLOGIC, INC. [ SYBX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) Chief Financial Officer
	3. Date of Earliest Transaction (Month/Day/Year) 11/10/2023	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Stock Option (right to buy)	\$33.45 <sup>(1)</sup>	11/10/2023		D		15,332		(2)	03/03/2032	Common Stock	15,332	(1)	0	D
Stock Option (right to buy)	\$9.3 <sup>(1)</sup>	11/10/2023		D		13,332		(3)	03/16/2033	Common Stock	13,332	(1)	0	D
Stock Option (right to buy)	\$9.3 <sup>(1)</sup>	11/10/2023		D		6,666		(4)	03/16/2033	Common Stock	6,666	(1)	0	D
Stock Option (right to buy)	\$1.85 <sup>(1)</sup>	11/10/2023		A		15,332		(2)	03/03/2032	Common Stock	15,332	(1)	15,332	D
Stock Option (right to buy)	\$1.85 <sup>(1)</sup>	11/10/2023		A		13,332		(3)	03/16/2033	Common Stock	13,332	(1)	13,332	D
Stock Option (right to buy)	\$1.85 <sup>(1)</sup>	11/10/2023		A		6,666		(4)	03/16/2033	Common Stock	6,666	(1)	6,666	D

Explanation of Responses:

- In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to \$1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
- These stock options vested 25% on the first anniversary of the March 3, 2022 grant date, and vest in 36 substantially-equal monthly installments thereafter, subject to the reporting person's continued employment through the applicable vesting date.
- The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027.
- These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met.

/s/ Michael Vangsted Jensen

11/14/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.